行情

ACER

ACER

Acer Therapeutic
NASDAQ

实时行情|Nasdaq Last Sale

4.330
0.000
0.00%
休市 16:00 01/17 EST
开盘
4.400
昨收
4.330
最高
4.850
最低
4.300
成交量
15.46万
成交额
--
52周最高
28.25
52周最低
1.871
市值
4,371.21万
市盈率(TTM)
-1.3331
分时
5日
1月
3月
1年
5年

分析师评级

6位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ACER 新闻

  • Here's Why We're A Bit Worried About Acer Therapeutics's (NASDAQ:ACER) Cash Burn Situation
  • Simply Wall St..01/05 12:00
  • Acer Therapeutics Says On Dec. 30 Submitted Formal Dispute Resolution Request To FDA Office Of New Drugs Appealing Previously-Announced CRL Regarding Co.'s EDSIVOTM NDA
  • Benzinga.01/02 21:23
  • Hedge Funds Are Betting On Acer Therapeutics Inc. (ACER)
  • Insider Monkey.2019/12/23 20:59
  • The Daily Biotech Pulse: Roche Gets US Antitrust Clearance For Spark Purchase, An Orphan Drug Designation For Prevail, Dynavax Names CEO
  • Benzinga.2019/12/17 12:56

更多

所属板块

生物技术和医学研究
-0.16%
制药与医学研究
+0.06%

热门股票

名称
价格
涨跌幅

ACER 简况

Acer Therapeutics Inc., formerly Opexa Therapeutics, Inc., is a pharmaceutical company. The Company is engaged in acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need. Its late-stage clinical pipeline includes Edsivo (celiprolol) and ACER-001. The Company is developing Edsivo for the treatment of vascular Ehlers-Danlos Syndrome (vEDS) in the United States. The Company is developing ACER-001, a pharmacologic treatment option for the treatment of Maple Syrup Urine Disease (MSUD). ACER-001 is an immediate-release formulation of sodium phenylbutyrate (NaPB) developed using a microencapsulation process. The Company is also developing ACER-001 for the treatment of Urea Cycle Disorders (UCD).
展开

Webull提供Acer Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。